SyntheticMR AB (publ) brings forward the publication date of the interim report for the period 1 January – 30 September 2024 to Monday, 18 November 2024.
The previously announced publication date for the report was Tuesday, 19 November 2024.
The board of directors of SyntheticMR AB (publ) (”SyntheticMR” or the ”Company”) has resolved to bring forward the publication date for the interim report for the third quarter of 2024 to Monday, 18 November 2024 due to the fact that the Company estimates that the report will be finalized earlier than previously expected. The Company's previously announced publication date for the report was Tuesday, 19 November 2024.
For more information, please contact:
Ulrik Harrysson, CEO
+46 70 529 29 87
[email protected]
Johanna Norén, CFO and Head of Investor Relations
+46 70 619 21 00
[email protected]
About SyntheticMR
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked, and FDA 510(k) cleared and SyMRI MSK is CE-marked. SyMRI 3D is 510(k)-pending and CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.
